{
    "nctId": "NCT04543799",
    "briefTitle": "Evaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer",
    "officialTitle": "SIESTA: A Pilot Observational Study to Investigate and Evaluate Sleep Quality in Cancer Patients Undergoing Hormonal Therapeutic Approaches: 1) Localized, Locally Advanced or Metastatic Prostate Cancer Receiving Treatment Including Androgen Deprivation Therapy 2) Full-resected Early (Stage I-III) Breast Cancer, Ductal Carcinoma in Situ or Lobular Carcinoma in Situ, Without Evidence of Residual Disease; Proven Postmenopausal Status",
    "overallStatus": "RECRUITING",
    "conditions": "Prostate Cancer, Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "difference in sleep quality",
    "eligibilityCriteria": "Inclusion Criteria for prostate cancer patients:\n\n* Written infor med consent according to International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures\n* Histologically proven adenocarcinoma of the prostate\n* Eastern Cooperative Oncology Group performance status 0-2\n* Adult male patient \\> 18 years of age, no upper age limit\n* Localized prostate cancer, locally advanced hormone-sensitive prostate cancer (HSPC) or metastatic hormone-sensitive prostate cancer (mHSPC)\n* ADT recipients are required to be scheduled to start ADT as standard of care (SOC) for metastatic or locally advanced prostate cancer\n* Scheduled to receive ADT treatment as SOC for \\> 6 months in combination with radiotherapy or oral AR-targeted systemic treatment as prescribed by the treating physician or radiotherapy alone\n\nExclusion Criteria for prostate cancer patients:\n\n* Histology with predominant small cell prostate cancer\n* Any previous treatment with ADT or oral AR-targeted agent (exception for short course anti-androgens - disease flare)\n* Have not received systemic treatment for any other cancer within the last 12 months\n* Active secondary malignancy that requires systemic therapy\n* Any clear contraindications present against treatment with ADT\n* Presence of sleep apnea syndrome, Apnea Hypopnea Index (AHI) \\>15 at baseline\n* Body mass index (BMI) \\> 35 at baseline\n* Severe respiratory disorders (asthma, Chronic obstructive pulmonary disease) at baseline\n* Severe cardiovascular disease or severe cardiovascular event \\< 6 months\n* History of stroke or other neurologic chronic illnesses \\< 6 months\n* Have demonstrated impaired mental status\n* History of brain tumours, presence of brain metastases or previous cranial irradiation\n* Night shift workers\n* Excessive lifestyle: massive coffee intake at night, regular excessive cigarette and alcohol consumption in the evening\n* Unhealthy sleep hygiene\n* Nocturia (the urgent need to urinate more than 2 times during the main sleep period at night) at baseline\n* Present diagnosis of depression or psychiatric illness pharmacologically treated\n* Diagnosis of insomnia and chronic intake of hypnotic medication at baseline\n* Chronic intake of medications that are known to induce sleep disturbance (antihistamines of first generation, cortisone intake \\> 25 mg/day)\n* Any diagnosed condition that causes known sleep disturbance\n\nInclusion criteria for breast cancer patients\n\n* Written informed consent according to International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures\n* Women with full-resected early (stage I-III) epithelial BC, ductal carcinoma in situ or lobular carcinoma in situ, without evidence of residual disease\n* Eastern Cooperative Oncology Group performance status 0-2\n* Adult female patient \u2265 18 years of age, no upper age limit\n* Proven postmenopausal status (defined by absence of menstruation for at least 6 months and/or level of estradiol \\<40 pg/ml, or bilateral oophorectomy or ovarian irradiation for suppression of ovarian function)\n\nExclusion criteria for breast cancer patients\n\n* Non-epithelial BC or BC with mixed epithelial and non-epithelial histology\n* Previous chemotherapy at any time, in treatment with ET at not standard dosage\n* Have received systemic treatment for any other cancer within the last 12 months\n* Active secondary malignancy that requires systemic therapy\n* Presence of sleep apnea syndrome, Apnea Hypopnea Index (AHI) \\>15 at baseline\n* Body mass index (BMI) \\> 35 at baseline\n* Severe respiratory disorders (asthma, Chronic obstructive pulmonary disease) at baseline\n* Severe cardiovascular disease or severe cardiovascular event \\< 6 months\n* History of stroke or other neurologic chronic illnesses \\< 6 months\n* Have demonstrated impaired mental status\n* History of brain tumours, presence of brain metastases or previous cranial irradiation\n* Night shift workers\n* Excessive lifestyle: massive coffee intake at night, regular excessive cigarette and alcohol consumption in the evening\n* Unhealthy sleep hygiene\n* Nocturia (the urgent need to urinate more than 2 times during the main sleep period at night) at baseline\n* Present diagnosis of depression or psychiatric illness pharmacologically treated\n* Diagnosis of insomnia and chronic intake of hypnotic medication at baseline\n* Chronic intake of medications that are known to induce sleep disturbance (antihistamines of first generation, cortisone intake \\> 25 mg/day) or any diagnosed condition that causes known sleep disturbance",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}